CD163 and neoplasm: Interestingly, the comparison of marker cluster densities of patients whose tumor subtypes differed between primary and BCLM to those patients with consistent subtypes revealed that CD68+MMP9+ in the primary was lower in patients with differing ER subtype whereas BCLM CD163+MMP9+ and HIF1α+ were lower in patients with differing HER2 subtype.